These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35038601)

  • 21. Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.
    Misra DP; Gasparyan AY; Zimba O
    Rheumatol Int; 2020 Nov; 40(11):1741-1751. PubMed ID: 32880032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine.
    Reyes AZ; Hu KA; Teperman J; Wampler Muskardin TL; Tardif JC; Shah B; Pillinger MH
    Ann Rheum Dis; 2021 May; 80(5):550-557. PubMed ID: 33293273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study.
    Mareev VY; Orlova YA; Plisyk AG; Pavlikova EP; Akopyan ZA; Matskeplishvili ST; Malakhov PS; Krasnova TN; Seredenina EM; Potapenko AV; Agapov MA; Asratyan DA; Dyachuk LI; Samokhodskaya LM; Mershina ЕА; Sinitsyn VE; Pakhomov PV; Zhdanova EA; Mareev YV; Begrambekova YL; Kamalov АА
    Kardiologiia; 2021 Mar; 61(2):15-27. PubMed ID: 33734043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colchicine may not be effective in COVID-19 infection; it may even be harmful?
    Cumhur Cure M; Kucuk A; Cure E
    Clin Rheumatol; 2020 Jul; 39(7):2101-2102. PubMed ID: 32394215
    [No Abstract]   [Full Text] [Related]  

  • 26. Potential Role of Colchicine in Combating COVID-19 Cytokine Storm and Its Ability to Inhibit Protease Enzyme of SARS-CoV-2 as Conferred by Molecular Docking Analysis.
    Kamel NA; Ismail NSM; Yahia IS; Aboshanab KM
    Medicina (Kaunas); 2021 Dec; 58(1):. PubMed ID: 35056328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review.
    Nas K; Eryilmaz N; Geyik MF; Altaş A
    Rheumatol Int; 2021 Apr; 41(4):811-817. PubMed ID: 33611657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colchicine: A potential therapeutic tool against COVID-19. Experience of 5 patients.
    Montealegre-Gómez G; Garavito E; Gómez-López A; Rojas-Villarraga A; Parra-Medina R
    Reumatol Clin (Engl Ed); 2021; 17(7):371-375. PubMed ID: 34301378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19 in patients with gout on colchicine.
    Pelechas E; Drossou V; Voulgari PV; Drosos AA
    Rheumatol Int; 2021 Aug; 41(8):1503-1507. PubMed ID: 34089357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colchicine and risk of COVID-19-associated hospitalization.
    Chang HC; Gau SY
    J Med Virol; 2023 Mar; 95(3):e28690. PubMed ID: 36946507
    [No Abstract]   [Full Text] [Related]  

  • 32. Frequency and severity of COVID-19 in patients with various rheumatic diseases treated regularly with colchicine or hydroxychloroquine.
    Oztas M; Bektas M; Karacan I; Aliyeva N; Dag A; Aghamuradov S; Cevirgen SB; Sari S; Bolayirli M; Can G; Hatemi G; Seyahi E; Ozdogan H; Gul A; Ugurlu S
    J Med Virol; 2022 Jul; 94(7):3431-3437. PubMed ID: 35315100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19.
    Kow CS; Hasan SS
    Rheumatol Int; 2021 Mar; 41(3):677-678. PubMed ID: 33388902
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.
    Reis G; Dos Santos Moreira-Silva EA; Silva DCM; Thabane L; Milagres AC; Ferreira TS; Dos Santos CVQ; de Souza Campos VH; Nogueira AMR; de Almeida APFG; Callegari ED; de Figueiredo Neto AD; Savassi LCM; Simplicio MIC; Ribeiro LB; Oliveira R; Harari O; Forrest JI; Ruton H; Sprague S; McKay P; Glushchenko AV; Rayner CR; Lenze EJ; Reiersen AM; Guyatt GH; Mills EJ;
    Lancet Glob Health; 2022 Jan; 10(1):e42-e51. PubMed ID: 34717820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RE: Colchicine and risk of hospitalization due to COVID-19: A population-based study.
    Sáenz-Aldea M; Salgado-Barreira Á; Taracido-Trunk M; Piñeiro-Lamas M; Herdeiro MT; Portela-Romero M; Saez M; Figueiras A
    J Med Virol; 2023 Apr; 95(4):e28741. PubMed ID: 37185845
    [No Abstract]   [Full Text] [Related]  

  • 36. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.
    Saiz-Rodríguez M; Peña T; Lázaro L; González Á; Martínez A; Cordero JA; Vicente JT; Richard F; Coma MJ; de Frutos M; Labrador J; Pueyo A
    Trials; 2020 Jul; 21(1):632. PubMed ID: 32646502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of colchicine on mortality in patients with COVID-19 - A systematic review and meta-analysis.
    Zein AFMZ; Raffaello WM
    Diabetes Metab Syndr; 2022 Feb; 16(2):102395. PubMed ID: 35078098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation.
    Bonaventura A; Vecchié A; Dagna L; Tangianu F; Abbate A; Dentali F
    Inflamm Res; 2022 Mar; 71(3):293-307. PubMed ID: 35113170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reducing length of hospital stay with colchicine.
    Karakaş Ö; Erden A; Güven SC; Armağan B; Sahiner ES; Kurtipek AC; Inan O; Gemcioglu E; Ateş İ; Omma A; Küçüksahin O
    J Infect Dev Ctries; 2022 Jan; 16(1):57-62. PubMed ID: 35192522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.